These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 1311436)

  • 1. Protection of cisplatin-induced neuropathy: recent developments.
    Hamers F; Neijt J; Gispen W
    Pathol Biol (Paris); 1992 Nov; 39(9):829-30. PubMed ID: 1311436
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacological interventions to reduce platinum-induced toxicity.
    Tognella S
    Cancer Treat Rev; 1990 Sep; 17(2-3):139-42. PubMed ID: 2176930
    [No Abstract]   [Full Text] [Related]  

  • 3. Rationale for the use of the ACTH4-9 analogue ORG 2766 in the treatment of diabetic neuropathy.
    Bravenboer B; Erkelens DW; Gispen WH
    Neth J Med; 1992 Dec; 41(5-6):255-8. PubMed ID: 1337372
    [No Abstract]   [Full Text] [Related]  

  • 4. A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer.
    Roberts JA; Jenison EL; Kim K; Clarke-Pearson D; Langleben A
    Gynecol Oncol; 1997 Nov; 67(2):172-7. PubMed ID: 9367703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interventions for preventing neuropathy caused by cisplatin and related compounds.
    Albers J; Chaudhry V; Cavaletti G; Donehower R
    Cochrane Database Syst Rev; 2007 Jan; (1):CD005228. PubMed ID: 17253547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity.
    Gandara DR; Perez EA; Weibe V; De Gregorio MW
    Semin Oncol; 1991 Feb; 18(1 Suppl 3):49-55. PubMed ID: 1848372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurotoxicity is not enhanced by increased dose intensities of cisplatin administration.
    Hilkens PH; van der Burg ME; Moll JW; Planting AS; van Putten WL; Vecht CJ; van den Bent MJ
    Eur J Cancer; 1995; 31A(5):678-81. PubMed ID: 7640038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of an ACTH(4-9) analogue on cisplatin neuropathy of longstanding duration: a phase II study.
    Hilkens PH; van der Burg ME; Moll JW; van den Bent MJ; van Putten WL; Vecht CJ
    Clin Neurol Neurosurg; 1995 May; 97(2):139-41. PubMed ID: 7656487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine.
    Sastry J; Kellie SJ
    Pediatr Hematol Oncol; 2005; 22(5):441-5. PubMed ID: 16020136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.
    Links M; Lewis C
    Drugs; 1999 Mar; 57(3):293-308. PubMed ID: 10193684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin-induced neuropathy in mature rats: effects of the melanocortin-derived peptide ORG 2766.
    Hamers FP; Pette C; Bravenboer B; Vecht CJ; Neijt JP; Gispen WH
    Cancer Chemother Pharmacol; 1993; 32(2):162-6. PubMed ID: 8387400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of the use of chemoprotectants in cancer chemotherapy.
    Lewis C
    Drug Saf; 1994 Sep; 11(3):153-62. PubMed ID: 7811398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of an ACTH (4-9) analogue on development of cisplatin neuropathy in testicular cancer: a randomized trial.
    van Gerven JM; Hovestadt A; Moll JW; Rodenburg CJ; Splinter TA; van Oosterom AT; Keizer L; Drogendijk TE; Groenhout CM; Vecht CJ
    J Neurol; 1994 Jun; 241(7):432-5. PubMed ID: 7931444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin neurotoxicity.
    Mollman JE
    N Engl J Med; 1990 Jan; 322(2):126-7. PubMed ID: 2152970
    [No Abstract]   [Full Text] [Related]  

  • 15. The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo.
    Hovestadt A; van der Burg ME; Verbiest HB; van Putten WL; Vecht CJ
    J Neurol; 1992 Mar; 239(3):143-6. PubMed ID: 1315383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of the neuropeptide ORG.2766 in the prevention and treatment of cisplatin-induced neurotoxicity in rats.
    Gerritsen van der Hoop R; de Koning P; Boven E; Neijt JP; Jennekens FG; Gispen WH
    Eur J Cancer Clin Oncol; 1988 Apr; 24(4):637-42. PubMed ID: 2838292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Glutathione chemoprotection therapy against CDDP-induced neurotoxicity in patients with invasive bladder cancer].
    Sumiyoshi Y; Hashine K; Kasahara K; Karashima T
    Gan To Kagaku Ryoho; 1996 Sep; 23(11):1506-8. PubMed ID: 8854791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurotrophic effects of ACTH/MSH neuropeptides.
    de Wied D
    Acta Neurobiol Exp (Wars); 1990; 50(4-5):353-66. PubMed ID: 1966658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACTH/MSH like peptides in the treatment of cisplatin neuropathy.
    Gispen WH; Hamers FP; Vecht CJ; Jennekens FG; Neyt JP
    J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):179-83. PubMed ID: 1326318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Administration of the cytoprotectant amifostine.
    Lindemann K
    Clin J Oncol Nurs; 1998 Jul; 2(3):101-4. PubMed ID: 10232150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.